CBD in cats faces a regulatory maze, despite growing safety data

Cannabinoid use in cats remains a gray zone for veterinary medicine, and the confusion is increasingly regulatory rather than purely scientific. In a recent Veterinary Practice News commentary, veterinarian and cannabis researcher Trina Hazzah argues that many clinicians are reluctant to discuss or recommend CBD for cats because they fear professional or legal consequences, despite a growing body of feline safety research and steady pet parent interest. (veterinarypracticenews.com)

That tension has been building for years. Federally, the FDA has not approved any CBD-containing drug for animal use, and the agency has also said CBD cannot simply be treated like a routine ingredient in food or feed under current law. The American Association of Veterinary State Boards has likewise concluded that the legal landscape is too inconsistent for uniform model regulation, describing a patchwork of state-by-state approaches and issuing guidance rather than firm model rules. (fda.gov)

The Veterinary Practice News article makes the case that this uncertainty leaves veterinarians on the sidelines while pet parents seek advice elsewhere, including retail staff, social media, and human cannabis dispensaries. That concern is especially relevant in cats, where product selection, flavoring agents, THC exposure, and labeling accuracy can all materially affect safety. AAVSB guidance says that if veterinarians recommend a specific CBD product, they should verify third-party testing for label accuracy and contaminants, and document clearly when a product is not FDA approved. (veterinarypracticenews.com)

On the science side, the evidence base is still early, but it is no longer empty. Published studies have found that healthy cats tolerated escalating oral cannabinoid doses in controlled settings, and another study reported tolerability with long-term daily CBD feeding in healthy cats. More recently, investigators published a randomized, placebo-controlled crossover study of a CBD/CBDA-rich hemp paste in cats with osteoarthritic pain, adding to the small but growing clinical literature in feline patients. What remains limited is the kind of large, condition-specific efficacy data and standardized product oversight that would make routine clinical adoption easier. (pmc.ncbi.nlm.nih.gov)

Regulatory variation adds another layer. California has been one of the clearest examples of movement at the state level: AB 2215, signed in 2018, protected veterinarians from discipline solely for discussing cannabis with clients, and AB 1885, signed in 2022, expanded protections around recommending cannabis for animal use under specified conditions. But those state-level openings do not change the underlying federal reality that there is still no FDA-approved animal CBD drug, and other states remain far less explicit. (kalra.asmdc.org)

Industry and regulatory bodies have tried to fill the gap with guardrails instead of endorsements. AAVSB’s guidance emphasizes that veterinarians must follow their own jurisdiction’s standards of practice, inform clients when products are not FDA approved, and use extra caution around product quality. State board FAQs and professional resources also continue to warn that legalization for human use does not automatically extend to animals. In other words, the profession is being asked to navigate consumer demand, emerging evidence, and legal ambiguity all at once. (aavsb.org)

Why it matters: For veterinary teams, this is less a fringe issue than a daily communication problem. Pet parents are already asking about cannabinoids for pain, anxiety, appetite, and mobility, especially in older cats. If clinicians avoid the topic entirely, those conversations may shift to less reliable sources, increasing the risk of inappropriate dosing, THC exposure, toxic excipients, or delayed use of proven therapies. The bigger issue is that regulation has not kept pace with demand or with the early-stage science, leaving veterinarians responsible for risk management without a clear national framework. (veterinarypracticenews.com)

What to watch: The next phase will likely hinge on three things: more feline efficacy studies, clearer state board policies on what veterinarians may recommend, and any federal move to create a workable pathway for CBD products in animal health. Until then, expect continued caution from clinicians, continued interest from pet parents, and continued pressure on regulators to reduce the mismatch between what’s being used in practice and what’s formally authorized. (pmc.ncbi.nlm.nih.gov)